Binding of echovirus 1 (EV1, a non-enveloped RNA virus) to the α2β1 integrin on the cell surface is followed by endocytic internalization of the virus together with the receptor. Here, video-enhanced live microscopy revealed the rapid uptake of fluorescently labelled EV1 into mobile, intracellular structures, positive for green fluorescent protein-tagged caveolin-1.
INTRODUCTION
Viruses that enter host cells by endocytosis are important tools in studies of membrane traffic in animal cells. Recently, they have been used to identify novel endocytic mechanisms that bypass the classical clathrin-mediated uptake processes (Pelkmans et al., 2001; Meier et al., 2002) . We have previously reported echovirus 1 (EV1) to be one of the viruses entering host cells via caveolar endocytosis (Marjomäki et al., 2002; Upla et al., 2004) ; however, the cellular mechanisms involved in the process are still incompletely defined.
Echoviruses are human pathogens that can cause meningitis, encephalitis, rash and mild respiratory and enteric infections (Grist et al., 1978) . Echoviruses belong to the Picornavirus family of small (30 nm), non-enveloped, positive-stranded RNA viruses. They include such significant pathogens of humans and livestock as polioviruses (PV), rhinoviruses (HRV), hepatitis A virus (HAV) and foot-and-mouth disease viruses (FMDV) . In spite of their close structural relationships, a variety of entry routes into host cells, including clathrin-mediated endocytosis, caveolae and lipid rafts, are employed by different picornaviruses (DeTulleo and Kirchhausen, 1998; Joki-Korpela et al., 2001; Marjomäki et al., 2002; Stuart et al., 2002) .
EV1 recognizes the α2I domain of the α2β1 integrin, a collagen receptor, on the cell surface (Bergelson et al., 1994) , leading to uptake of the receptor and the virus through caveolaemediated endocytosis (Marjomäki et al., 2002) . Caveolae are invaginations of the plasma membrane approximately 50-80 nm in size (Palade, 1953) , and their main protein component is caveolin-1 (Rothberg et al., 1992) . They are involved in various signalling processes and in uptake of cholesterol (Murata et al., 1995; Simons and Toomre, 2000) . The other ligands include autocrine motility factor (AMF) (Benlimame et al., 1998) and cholera toxin (CTX) 4 (Montesano et al., 1982) as well as microbial pathogens such as type FimH-expressing E. coli (Shin et al., 2000) , simian virus 40 (SV40) (Anderson et al., 1996) and EV1 (Marjomäki et al., 2002) . Even though caveolae are relatively stable under normal conditions, interaction of the ligand with a receptor can trigger their internalization in the presence of protein phosphorylation, dynamin II GTPase and actin (Parton et al., 1994; Henley et al., 1998) . The endocytosed caveolar vesicles accumulate in a discrete population of pre-existing, caveolin-1-containing mobile structures called caveosomes (Pelkmans et al., 2001) , which take up extracellular ligands such as CTX (Nichols, 2002) , AMF (Le et al., 2002) , SV40 and cholesterol (Pelkmans et al., 2001) .
CTX is further sorted from caveosomes to the Golgi complex (Le and Nabi, 2003) , SV40 (Pelkmans et al., 2001) and AMF (Le and Nabi, 2003) are transported to the endoplasmic reticulum (ER) whereas the location of EV1 before initiation of replication has thus far remained unclear. Picornaviruses are known to undergo structural alterations during receptor interactions and entry, leading to the uncoating of the virus particle and release of the viral genome into the cytoplasm required for subsequent translation and replication events (Hogle, 2002) . Uncoating of pH-sensitive picornaviruses, such as HRVs, takes place in the acidic pH environment of endosomes or by rupture of endosomes (Schober et al., 1998; Huber et al., 2001 ). However, since EV1 is acid-pH-stable, it must rely on other mechanisms and possibly other organelles for entry and uncoating.
Here, the uptake mechanism of EV1 was further studied using a fluorescently labelled virus and GFP-constructs of caveolin-1 in a real-time live microscopy, dominant negative mutants of cellular proteins, and different inhibitors of cellular functions. We show that after binding to the α2β1 integrin EV1 is rapidly endocytosed into caveosomes, a process dependent on dynamin II, cholesterol and protein phosphorylation events but not requiring an intact actin cytoskeleton or microtubules. The viral capsid proteins and RNA are found in the caveosomes until the initiation of viral replication. The EV1 entry process provides a new model for studies on endocytosis of microbial pathogens and caveosome function.
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MATERIALS AND METHODS
Cell culture, virus purification and fluorescent labelling
Echovirus 1 (EV1; Farouk strain) was obtained from the American Type Culture Collection (ATCC). The virus was grown in a green monkey kidney (GMK; ATCC) cell line and purified in sucrose gradients (Pietiäinen et al., 2000) . The fluorescent labelling of purified EV1, with a ten times higher molar concentration of Texas Red-X succinimidyl ester (Molecular Probes) and Alexa Fluor (AF)-594 succinimidyl ester (Molecular Probes), was performed as described by Pelkmans et al. (2001) . The infectivity of the labelled virus (AF-EV1) was determined by plaque titration, and the efficiency of labelling was calculated from the absorbance spectrum. To reveal the labelled proteins, a sample of AF-EV1 was run in a 12% SDS-PAGE gel that was stained with a silver staining kit (Amersham Pharmacia Biotech) after UV exposure. SV40 was propagated in a green monkey kidney cell line (CV-1; ATCC), purified and labelled with Cy5, FITC or AF-594 dyes as reported (Pelkmans et al., 2001 ).
Most of the experiments were performed in the CV-1 cell line (green monkey kidney cell line; ATCC), which was maintained as described earlier (Pelkmans et al., 2001) . The SAOS-α2β1 cell line was generated from SAOS cells (ATCC), which do not normally express the α2 integrin subunit (Ivaska et al., 1999) . Infections of the cells with EV1 and SV40 were performed in appropriate cell culture media supplemented with 1% FCS. Multiplicity of infection (MOI) of 2 or 20 was used in EV1 infections. The EV1 infections were performed for 1 h at 4°C to allow the binding of the virus prior to removal of the unbound virus by washing and transferring the cells to 37°C.
Antibodies and immunofluorescence microscopy
The following primary antibodies were used in the immunofluorescent staining: rabbit anti-EV1 antibody (Marjomäki et al., 2002) to detect EV1 capsid proteins, rabbit anti-caveolin-1 antibody (N-20; Santa Cruz Biotechnology), mouse monoclonal anti-caveolin-1 antibody (2234; Transduction Laboratories), anti-CD49b monoclonal antibody recognizing the I domain of the α2 integrin subunit (Immunotech), AF-488-labelled (Molecular Probes) mouse anti-α2 monoclonal antibody (MCA2025, Serotec), mouse anti-p230 monoclonal antibody for detecting the trans-Golgi network (Transduction Laboratories), mouse monoclonal antibody against PDI (ID3; from S. Fuller), rabbit anti-transferrin antibody (Behring Institute), goat antibody against syntaxin 17 (Steegmaier et al., 1998) , rabbit antiserum against cationindependent-mannose-6-phosphate receptor (CI-MPR) (Marjomäki et al., 1990) , and mouse monoclonal antibody for CD63 (Zymed).
AF-488-conjugated cholera toxin subunit B (0.5 or 10 µg/ml) (Molecular Probes) was incubated with CV-1 cells together with EV1 for 1 h at 4°C and the cells were then transferred to 37°C. Lysotracker Red DND99 (100 nM) (Molecular Probes) was added to EV1-infected cells for 30 min at 37°C. Holo-transferrin (Sigma) was incubated with cells in the growth medium at a concentration of 1 mg/ml for 10 min at 37°C. AF-594-labelled SV40 (10 3 PFU/cell) was added to the cells for 2 h at 37°C prior to EV1 binding to cells in cold. For nocodazole assay, CV-1 and SAOS-α2β1 cells were treated with nocodazole (33µM) for 30 min at 37°C, and incubated with Cy5-SV40 (0.3 mg/ml) for 1.5 h at 37°C prior to addition of EV1 at 37°C. Depolymerization of microtubules was verified by tubulin labelling. After incubation at 37°C for an appropriate time, the cells were fixed with 4% formaldehyde (Sigma), quenched with 50 mM NH 4 Cl and permeabilized with 0.05% (w/v) saponin (Sigma) or 0.3% Triton-X-100 (Sigma) in PBS. immunofluorescence microscope containing a CCD camera (Hamamatsu), using a U Plan FI 20X/0.5 Ph1 objective and the Open Lab 2.2.5 program (Improvision). At least four sections containing ~300 cells were counted for each specimen.
Transfections
The transient transfections of CV-1 cells were performed for 14 h before EV1 infection with Fugene 6 (Roche) or Superfect (Qiagen) following manufacturers' protocols. N-or Cterminally GFP-tagged constructs of caveolin-1 (GFP-caveolin-1 and caveolin-1-GFP, respectively) (Pelkmans et al., 2001) were used in (real-time) microscopy and infectivity measurements. HA-tagged caveolin-3 and caveolin-3 DGV (Roy et al., 1999) were obtained from Robert Parton (University of Queensland, Brisbane, Australia), GFP-dynamin 2aa and GFP-dynamin 2aa K44A (Cao et al., 1998; Ochoa et al., 2000) from Mark McNiven (Mayo Clinic, Rochester, USA), Eps15-GFP and Eps15E∆95/295-GFP (Benmerah et al., 1999) were from Alice Dautry-Varsat (Institute Pasteur, Paris, France) and adaptor protein 180 mutant (AP180C construct) (Ford et al., 2001 ) from Dieter Blaas (University of Vienna, Austria).
The EV1 infection was allowed to proceed in transfected cells for 6 h at 37°C prior to immunostaining or collection the samples for the plaque assay. The collected images were further processed using Open Lab 2.2.5 software and edited to QuickTime 5 format. The colour for AF-EV1 was set as red (except as white in video corresponding to Fig. 2D ), and the colour for SV40 and GFP constructs as green, prior to merging of images, which resulted in a yellow colour when colocalization occurred. For calculating movements and velocities, the location of the object was marked in several frames, which were then merged to measure the distance travelled between frames. To quantitate colocalization, Pearson's coefficient was calculated using the Open Lab program.
Drug treatments
CV-1 cells were incubated with different drugs for 30 min at 37°C before addition of EV1 for 1 h at 4°C, which was followed by a 6-h incubation period at 37°C. Concentrations of the drugs were 5 µM bisindolylmaleimide (Sigma), 5 µg/ml of cytochalasin D (Sigma), 25-250 µM genistein (Sigma), 1 µM latrunculin A (Molecular Probes), 0.5 µM jasplakinolide (Molecular Probes), 10 mM methyl-β-cyclodextrin (Sigma), 33 µM nocodazole (Sigma), 25 µg/ml nystatin (Sigma) together with 10 µg/ml progesterone (Sigma), 1 µM okadaic acid (Sigma), 10 µM safingol (Sigma) and 1 mM sodium orthovanadate (Calbiochem).
Immunofluorescent staining and plaque titration (Marjomäki et al., 2002) were performed for collected samples.
For dose-dependent assay with drugs affecting the actin cytoskeleton, poly-L-lysine -coating of the coverslips was performed to prevent the deattachment and rounding of the cells. 1µg/ml of poly-L-lysine in PBS was added on coverslips in the previous day and washed away before plating of the CV-1 cells. Actin drugs (cytochalasin D; 1-7 µg/ml, latrunculin A; 0.13-1 µM and jasplakinolide; 0.1-0.75 µM) were added to the cells for 30 min at 37°C prior to EV1 infection and immunofluorescent staining assay performed as described above.
For testing the effects of brefeldin A (BFA, Sigma), the CV-1 cells were incubated in the presence of the drug (0.5-2 µg/ml) for 1 h at 37°C. EV1 infection and detection of infected cells were performed as above. To investigate the time-scale of its action, BFA was added to cells at different time-points of infection (-1, 0, 1, 2, 3, 4 h). The infections were allowed to proceed for 6 h at 37°C prior to the plaque assay and/or immunofluorescent staining of infected cells. To study the effect of BFA on the intracellular localization of EV1, BFA was added 1 h prior to infection or 1 h p.i. To investigate whether SV40 is localized into the same cellular structures with EV1, BFA was added 1 h p.i. to the cells infected with Cy5-SV40 and EV1 as described earlier in the Materials and Methods, and the infections were let to proceed until 3-4 h prior to fixation and immunofluorescent staining.
Infection titration and immunoblotting
CV-1 cells, infected with EV1 (MOI 20), were collected at different time-points and after three freeze-thaw cycles, the amount of virus was determined by quantitative plaque analysis (Marjomäki et al., 2002) . For Western blot analysis, infected cells were collected at appropriate time-points, boiled in 2x SDS-lysis buffer and electrophoresed in a 12% SDS-PAGE gel. The immunoblotted proteins were reacted with anti-EV1 antibody and detected using horseradish-peroxidase (HRP) conjugated swine anti-rabbit IgG (DakoCytomation).
Signals were detected using an enhanced chemiluminescence Western blotting detection kit (Amersham Pharmacia Biotech).
Sucrose gradient sedimentation analysis
Metabolic labelling of purified EV1 and PV1 was performed using [ 35 S]-methionine (50 µCi/ml; Pharmacia Biotech) (Marjomäki et al., 2002) . To prepare 135S and 80S control particles for the gradients, to allow binding of the virus prior to incubation period of 1-2 h at 37°C. Preparation of the samples and ultracentrifugation in linear 5-20% sucrose gradients were performed as detailed elsewhere (Marjomäki et al., 2002) .
Fluorescent in situ hybridization
The full-length cDNA clone of EV1 in the pSPORT 1 vector (Ohman et al., 2001 ) was provided by Jeffrey Bergelson (Children's Hospital of Philadelphia, Philadelphia, USA). The negative-polarity RNA strand was transcribed using SP6 polymerase (Promega) from linearized EV1 cDNA in the presence of FITC-labelled UTP (0.35 mM; Molecular Probes) or treatment, the probe was purified as described earlier (Bolten et al., 1998) . To perform fluorescent in situ hybridization (FISH), the untransfected and GFP-caveolin-1-transfected CV-1 cells were infected with EV1 and the hybridization reaction was performed for 12 h at 42°C in the dark, in the presence of the labelled probe (Bolten et al., 1998) . After removal of the unbound probe, the cells were mounted with 2.5% DABCO (Sigma) in pH-buffered glycerol and visualized using a confocal microscope (Leica) as described above.
RESULTS
EV1 is endocytosed into CV-1 cells that express the viral receptor
Most of the experiments in this study were performed in CV-1 cells, a green monkey kidney cell line in which the caveolar pathway of SV40 has been characterized (Pelkmans et al., 2001; Pelkmans et al., 2002) . As shown in Figure 1A Staining with anti-EV1 antibody illustrated that some of these organelles also contained EV1
( Figure 1A , 3rd row). Thus, the virus interacted with the CV-1 cells in a similar manner as with SAOS-α2β1 cells, which we have used in previous studies of EV1 internalization (Marjomäki et al., 2002; Upla et al., 2004) .
EV1 caused rapid and efficient infection of the CV-1 cells, and production of infectious progeny virus particles was observed after 3 h post-infection (p.i.) ( Figure 1B ). Six hours after infection most of the cells (approximately 75%) showed cytopathic effect and stained intensively with an antibody against EV1 (our unpublished results). Immunoblotting using antibodies against the EV1 capsid proteins revealed synthesis of structural proteins starting about 3 h after the infection ( Figure 1C ).
Properties of fluorescently labelled EV1
To follow the entry process by real-time fluorescence microscopy, EV1 was labelled with the amino-reactive, fluorescent dyes Texas Red (TxR) and Alexa Fluor-594 (AF). The label was bound to outer capsid proteins VP1 and VP2/VP3 of a virus particle (Figure 2A) , and based on absorbance spectra, each viral particle carried 500-900 dye molecules. Labelling did not have a significant effect on the infectivity of the virus, as in plaque titration assay the titre of AF-EV1 was at least 85% of that of unlabelled virus. When fluorescently labelled EV1 was incubated with cells at 4°C, small dots and some larger spots were observed on the cells, probably representing single viral particles and virus clusters, respectively ( Figure 2B ).
To investigate whether the fluorescently labelled EV1 was able to enter cells similarly to the unlabelled virus, we first used the SAOS-α2β1 cells, employed in our previous studies (Marjomäki et al., 2002) . The cells, which were incubated for 2 h at 37°C with fluorescently labelled EV1, exhibited colocalization of the virus with α2β1 integrin and caveolin-1 in confocal microscopy ( Figure 2C ). Evidently, the labelled virus behaved similarly to the native virus with respect to colocalization with caveolin-1 and α2β1 integrin in SAOS-α2β1 cells.
Echovirus 1 rapidly moves to caveolin-1-containing structures after binding to the cell surface
To synchronize the uptake process, we incubated CV-1 cells with AF-EV1 for 1 h at 4°C
prior to transfer to 37°C in a preheated chamber of a real-time microscope. Some of the small dots on the cell surface could now be seen to join larger spots of different sizes. While most of these spots remained stationary, some moved out of the focal plane, suggesting endocytic uptake ( Figure 2D , video Fig2D_v). When the experiment was repeated in GFP-tagged caveolin-1-expressing CV-1 cells, the majority of virus particles bound to the cells at 4°C did not colocalize with caveolin-1 on the cell surface. However, after 10 min at 37°C, viruses moved into caveolin-1-positive mobile structures in the cell periphery and deeper in the 15 cytoplasm. These structures were likely to be intracellular based on their mobility and their location ( Figure 2E , video Fig2E_v).
Kinetics of EV1 traffic in the cells
Within the first 20 min at 37˚C, the viruses became increasingly associated with larger, caveolin-1-positive structures ( Figures 3A and 3B ). By focusing, it became clear that the viruses were located in intracellular organelles. During an 8 to 22 min incubation at 37˚C the colocalization analysis of caveolin-1 and EV1 in live microscopy images revealed an increase of about 75% in Pearson's correlation, a figure related to the extent of overlap between the images (Manders et al., 1993) . While some of these virus-containing organelles were stationary, the majority were mobile. They typically performed random, short-distance movements of 3-6 µm or medium-distance movements of 9-14 µm ( Figure 3A -I, videos 
Colocalization of EV1 with CTX and SV40
Next, we determined whether the EV1-containing organelles would accumulate CTX, a ligand known to bind to a GM1 ganglioside and at least partially pass through caveosomes during transport to the Golgi complex (Nichols, 2002) . When incubated on the CV1 cells together for 1 h at 4˚C, followed by incubation at 37˚C, CTX and AF-EV1 were found to partially colocalize in small, dot-like structures at 30-60 min ( Figure 4A ). After 1 h, most of the CTX had accumulated in the perinuclear region, colocalizing with trans-Golgi as detected by a specific p230 antibody (2 h p.i.; Figure 4B ). Colocalization of EV1 with CTX was not observed within this region ( Figures 4A and 4B ). Nor did EV1 colocalize with marker for lysosomes (Lysotracker) at 2 h p.i., the rough ER (protein disulphide isomerase; PDI) at 2 h p.i. or smooth ER (syntaxin 17) at 3 h ( Figure 4B ) or 4 h p.i (our unpublished results).
Syntaxin 17 was also stained in AF-EV1 -infected SAOS-α2β1 cells without a notable colocalization with the virus (our unpublished results).
To further characterize the EV1-containing, caveolin-1-positive organelles, CV-1 cells were incubated simultaneously with EV1 and SV40. SV40 is known to remain on the plasma membrane caveolae for at least 20 min prior to endocytosis via caveolar vesicles to caveosomes in 40 min to 3 h Pelkmans et al., 2001) . To synchronize the entry processes of the more rapidly internalized EV1 and SV40, SV40 was preincubated with cells for 90 min to 2 h at 37˚C before inoculation of EV1 for 1 h at 4°C. The cells were then transferred back to 37°C to allow the infections to proceed. The localization of AF-SV40
(red) and EV1 (detected by immunofluorescence, green) was studied in fixed CV-1 cells by confocal microscopy ( Figure 5A ). While the viruses did not colocalize at the beginning of infection, partial colocalization was observed at 30 min after EV1 entry, and this increased during the next 2 h ( Figure 5A ). In live microscopy, cytoplasmic structures containing FITClabelled SV40 and AF-EV1 were observed 15 min after EV1 entry, and these increased in size with incubation time ( Figure 5B , video Fig5B_v1). The SV40-and EV1-positive structures also became more mobile about 1 h after EV1 entry (video Fig5B_v2) . This occurred somewhat later than in cells infected with EV1 alone, suggesting that SV40 coinfection may retard the entry process. Furthermore, the CV-1 cells and SAOS-α2β1 cells were treated for 30 min at 37˚C with nocodazole (33µM), a microtubule disrupting agent that does not affect the SV40 uptake to caveosomes but prevents its sorting from caveosomes to sER (Pelkmans et al., 2001) . The nocodazole-treated cells were infected with Cy5-SV40 for 90 min at 37˚C
prior to addition of EV1, and after incubation for 2-4 h at 37˚C, the cells were fixed and immunostained with antibodies against EV1. The presence of nocodazole increased the colocalization of EV1 and SV40 in both cell lines ( Figure 5C ), strongly supporting that the structures EV1 entered were caveosomes.
As a conclusion, the presence of caveolin-1, CTX, and SV40 in same intracellular organelles with EV1 demonstrated that EV1 entered caveosomes. The fast internalization of EV1 to caveosomes was similar to CTX but diverse from a slow uptake of SV40. The subsequent pathways are remarkably different, since SV40 is known to traffic to sER (Pelkmans et al., 2001; Norkin et al., 2002) and CTX was further sorted to the Golgi complex, but EV1 did not reach the Golgi or the (s)ER.
Dynamin II is involved in EV1 infection
Expression of mutant constructs of caveolin-1, caveolin-3, dynamin II and Eps15 was next used to analyse the cellular requirements for EV1 infection. Haemagglutin (HA)-tagged, truncated and dominant-negative caveolin-3 (cav-3 DGV ) (lacking the first 53 amino acids) disrupts lipid transport and causes depletion of lipid rafts, thus inhibiting caveolar endocytosis (Parton et al., 1997; Roy et al., 1999) . Cav-3 DGV showed 35% inhibition of EV1 infection ( Figure 6A ). Cav-3 DGV is known to inhibit SV40 infection in a very similar manner by approximately 30% (Roy et al., 1999) . In contrast to cav-3 DGV , N-terminally GFP-tagged caveolin-1 (GFP-caveolin-1) (Pelkmans et al., 2001) has similar overall distribution with wild-type caveolin-1 and it has been used in live microscopy studies of caveolar function (Thomsen et al., 2002) . Here, the outcome of GFP-caveolin-1 in EV1 infection was tested since it serves as a dominant negative inhibitor of SV40 entry (Pelkmans et al., 2001) In contrast to its effect on SV40, GFP-caveolin-1 did not affect the uptake (see Figures 3B and   9 ) and replication of EV1 (our unpublished results).
Dynamin II is a widely needed GTPase that acts both in clathrin-coated pit and caveolar internalization (Damke et al., 1994; Henley et al., 1998; Oh et al., 1998) . We found that the expression of the dominant-negative mutant of dynamin II, dyn2(K44A), inhibited EV1
infection by 75% in CV-1 cells ( Figure 6A ). In contrast, the dominant-negative deletion mutant of Eps15, Eps15(E∆95/295), which prevents formation of clathrin-coated vesicles (Benmerah et al., 1999) , did not inhibit EV1 infection ( Figure 6A ). The Eps15(E∆95/295) construct was functional since it inhibited transferrin endocytosis in the CV-1 cells (data not shown). In addition, a mutant of adaptor protein 180 (AP180C), that interferes clathrin route (Ford et al., 2001; Snyers et al., 2003) , was tested, and like Eps15, it had no significant effect as it inhibited the EV1 infection by approximately 7%. In addition, studies with dominant negative mutants of Eps15 and AP180 in SAOS-α2β1 cells strongly suggest that clathrinmediated pathway is not involved in the antibody-induced internalization of the viral receptor, α2β1 integrin (Upla et al., 2004 ). These results demonstrate the requirements for dynamin II as well as caveolin but not clathrin in the initiation of EV1 infection.
Role of cholesterol, signalling events and cellular cytoskeleton in EV1 infection
The effects of several inhibitors on EV1 infection were examined using immunofluorescence and the plaque titration assay ( Figure 6B ). The cells were pretreated with the drugs for 30 min at 37°C, and the drugs remained present during the entire infection period. First, to find whether cholesterol and lipid rafts play a role in EV1 infection, the combination of progesterone (Prog; a cholesterol synthesis inhibitor, 10 µg/ml) and nystatin (Nys; a cholesterol-sequestering drug, 25 µg/ml) (Simons and Toomre, 2000) was tested, showing inhibition by more than 50%. Further evidence for involvement of lipid rafts and/or caveolae was seen in treatment with 10 mM methyl-β-cyclodextrin (MBCD), which affects cholesterol distribution and destroys caveolae (Hailstones et al., 1998) , inhibiting EV1 infection almost completely (by 95%).
Internalization of caveolae depends on specific signalling events (Simons and Toomre, 2000) , including activation of protein kinase C (Mineo et al., 1998) and local tyrosine phosphorylation (Nomura and Fujimoto, 1999; Pelkmans et al., 2002 ). Here, we tested the effects of a broad-spectrum protein kinase C (PKC) inhibitor, bisindolylmaleimide (Bis; 5 µM), and a specific PKCα inhibitor, safingol (Saf; 10 µΜ). Both inhibitors prevented infection efficiently (≥ 80%), demonstrating the involvement of PKCα in the process ( Figure   6B ), as has also been observed in EV1 infection in SAOS-α2β1 cells (Upla et al., 2004) .
Moreover, genistein (Gen), a specific tyrosine kinase inhibitor, was able to block infection in a dose-dependent manner when studied by the immunofluorescence assay (proportion of infected cells in the presence of genistein: 250 µM: 0%, 100 µM: 13%, 50 µM 28%, 25 µM:
86%, no genistein: 100%)( Figure 6B ; 100 µM). Okadaic acid (OA; 1 µΜ), a general inhibitor of serine and threonine phosphatases that has been reported to increase caveolar internalization (Parton et al., 1994) did not have a significant effect. Unexpectedly, the treatment with sodium orthovanadate (NaOV; 1 mM), an inhibitor of protein tyrosine phosphatases that enhances the uptake of SV40 through caveolae (Pelkmans et al., 2002) , reduced EV1 infection by 70% ( Figure 6B ).
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As actin is known to mediate the internalization of the ligands from cell surface caveolae (Parton et al., 1994; Pelkmans et al., 2002) , we examined three agents interfering with actin function, latrunculin A (LatA, an actin monomer-sequestering drug, 1 µM), jasplakinolide (Jas, an actin polymer-stabilizing drug, 0.5 µM) and cytochalasin D (CytD, an inhibitor of actin polymerization, 5 µg/ml). A dose-dependent titration assay with these drugs showed no effect on EV1 infection in CV-1 cells ( Figures 6B and 6C ). Nocodazole, (Noco, 33 µM), a microtubule-disrupting agent, which prevents the transport of SV40 from caveosomes to the smooth ER (Pelkmans et al., 2001) had no inhibitory effect on EV1 infection ( Figure 6B ), even though tubular structures containing the virus have been observed in our live microscopy studies ( Figures 3A and 3B ).
We also carried out the series of experiments with brefeldin A (BFA), which is an inhibitor of caveolae-mediated endocytosis and a Golgi-disrupting agent (Dinter and Berger, 1998; Richards et al., 2002) . BFA prevented the EV1 infection completely even at low concentrations (0.5-2 µg/ml) ( Figure 6B ; 2 µg/ml). In an assay testing which stage of infectious cycle is affected by BFA, the drug (0.5µg/ml) exhibited more effective inhibition when added to EV1-infected CV-1 cells before 3 h p.i ( Figure 7A ). By confocal microscopy we observed that EV1 was able to enter the cells in the presence of BFA but the virus was found in large accumulations ( Figure 7B ). To further characterize these structures, the cells were pretreated with BFA prior to the infection and labelled with antibodies against caveolin-1, an endosomal pathway marker (CI-MPR) and a lysosomal marker (CD63). The organelles were positive for caveolin-1 but showed no staining for CI-MPR and CD63 (our unpublished results). Also, the localization of Cy5-SV40 and EV1 was examined in presence of BFA (added 1 h p.i) in CV-1 cells ( Figure 7B ) and SAOS-α2β1 cells (our unpublished results). In both cell lines, the BFA treatment caused SV40 and EV1 to accumulate to greater extent into the large structures mentioned above that labelled strongly positive for caveolin-1 ( Figure   7B ). Moreover, in the presence of BFA, newly synthesized viral RNA could not be detected in cells with fluorescent in situ hybridization even at 5 h p.i. (our unpublished results), when viral RNA was observed throughout the cytoplasm in EV1-infected, untreated control cells (see Figure 8C ).
From these results, we concluded that initiation of EV1 infection requires cholesterol as well as signalling events. Actin or microtubules did not appear to play a significant role in the initiation of EV1 infection. Brefeldin A, an agent blocking SV40 entry and infection (Norkin et al., 2002) , caused accumulation of EV1 into caveosome-like organelles and prevented the productive infection.
Colocalization of EV1 capsid proteins, viral RNA and caveolin-1 during virus entry
To follow disassembly of incoming virus particles, [ 35 S]methionine-labelled EV1 was allowed to interact with GMK cells, another green monkey kidney cell line, previously used in our studies (Xing et al., 2004) . Sucrose gradient sedimentation of cell surface-bound EV1
showed that binding did not trigger changes in the sedimentation of the virus since the majority of virus particles (85%) were in the 160S form, representing intact viral particles ( Figure 8A ). Polioviral (PV1) 135S and 80S particles were produced here as controls of a well-characterized picornavirus disassembly process (Hogle 2002 ) ( Figure 8A ). When EV1
was incubated with cells at 37°C for 1 h ( Figure 8B ), 35% of the particles were converted to the 135S form (lacking the VP4 capsid protein) and 20% to the 80S form (empty capsids without VP4 and viral genomic RNA). After 2 h of incubation at 37°C ( Figure 8B ), 30% of particles were in the 135S form and 30% in the 80S form. This data demonstrated that EV1 uncoating is a slow event compared with polioviruses (Hogle, 2002) , and it is likely initiated after the virus has been internalized.
Fluorescent in situ hybridization (FISH) (Bolten et al., 1998) with a negative-stranded RNA probe was used to detect the viral RNA genome in CV-1 cells ( Figure 8C ). Genomic RNA could be observed by confocal microscopy immediately after binding of the virus as small dots on the cell surface. Already after 15 min at 37°C, the viral RNA began to concentrate into larger intracellular accumulations throughout the cytoplasm (our unpublished results).
The size of the accumulations increased after 30 min, and they were also observed in the perinuclear region 1 h p.i. (Figure 8C ), whereas at 2 to 3 h p.i. some viral RNA could also be seen along the cell boundaries. A dramatic increase in the amount of viral RNA staining was observed in the cytoplasm at 4 h p.i. (Figure 8C ), consistent with the time of initiation of viral RNA replication (our unpublished results). Mock-infected control cells showed no background staining ( Figure 8C ).
The FISH technique was also used in combination with the detection of the fluorescent virus (AF-EV1) to follow the localization of viral RNA relative to the capsid proteins. Their colocalization could be convincingly observed 30-60 min after incubation of the infected cells at 37°C ( Figure 9A ). After 2 h p.i., the colocalization clearly diminished, possibly due to release of viral RNA from the virus capsids. To investigate whether the viral RNA-positive structures were caveosomes, in situ hybridization was carried out in EV1-infected, GFPcaveolin-1-transfected cells. Soon after incubation at 37°C, viral RNA was observed in small dots, without apparent colocalization with caveolin-1 (data not shown). Colocalization of viral RNA and caveolin-1 became more evident when the infection proceeded (30 min and 1 h p.i.; Figure 9B ), and when the size of the structures containing the RNA further increased (2 to 3 h p.i.; Figure 9B ). In cells overexpressing GFP-tagged caveolin-1, the colocalization persisted even longer, possibly implying that overexpression of caveolin-1 delays the initiation of viral replication (our unpublished results). At 4 h p.i., colocalization decreased, coinciding with the onset of viral RNA synthesis (our unpublished results).
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DISCUSSION
We showed that a human pathogen, EV1, enters host cells through a pathway dependent on caveosomes, dynamin II and signalling events but not requiring clathrin-coated pits, actin filaments or microtubules in the cell line used for the studies. Interestingly, EV1 uptake into caveosomes was much faster than that of SV40, a well-known virus model for caveolar endocytosis (Anderson et al., 1996; Pelkmans et al., 2001; Pelkmans et al., 2002) . EV1 was not observed to enter the Golgi complex, the ER or the lysosomes, instead remaining in caveosomes until the initiation of replication. This raises a question whether caveosomes, besides sorting of viruses and other ligands to the ER or the Golgi complex, could also act as a site for virus penetration and uncoating.
Our previous study (Marjomäki et al., 2002) showed that in SAOS-α2β1 cells, overexpressing the α2β1 integrin, the EV1 receptor, the virus entered caveolin-1-positive intracellular accumulations together with the receptor (Marjomäki et al., 2002) . Caveolar endocytosis requires dynamin (Henley et al., 1998) and is a clathrin-independent process.
However, dynamin-2 is not a specific marker of caveolar pathway since it is also needed for certain lipid raft-mediated endocytosis (Pelkmans and Helenius, 2003) and for pinching of clathrin-coated vesicles (Damke et al., 1994) . The experiment with dominant negative mutants of cellular proteins revealed that the infection was highly dependent on dynamin II, but unaffected by the Eps15 mutant (Benmerah et al., 1999) and the C-terminal mutant of AP180 (Ford et al., 2001; Snyers et al., 2003) , both known to interfere the clathrin route.
Accordingly, our earlier results showed that EV1 does not colocalize with transferrin, endosomal markers (Marjomäki et al., 2002) or lysosomes during entry. The requirement of dynamin may exclude the recently described dynamin-independent pathways (Sabharanjak et 25 al., 2002; Pelkmans and Helenius, 2003) in EV1 uptake. The caveolar endocytosis of EV1 was further verified by inhibition of the infection with drugs interfering with the cellular cholesterol balance, with lipid rafts and with caveolae, by colocalization of the virus together with α2β1 integrin in caveolin-1 positive intracellular structures in (live) fluorescence microscopy and by partial loss of viral infectivity (35%) in presence of a dominant-negative mutant of caveolin-3. Similar inhibition was obtained in a study where the effect of caveolin-3 DGV was tested on SV40 infection in CV-1 cells (Roy et al., 1999) . In contrast, N-terminally GFP-tagged caveolin-1, known to prevent caveolar entry of SV40 and progression of infection (Pelkmans et al., 2001) , did not alter EV1 uptake or infection. This suggests that either i) the molecular interactions initiating the entry process of EV1 via cell surface caveolae might differ remarkably from SV40 or ii) parallel, non-caveolar entry mechanisms may also exist. Such an alternative pathway would need to be dynamin-and lipid raftdependent, and result in virus transfer into caveosomes. Whether the alternative pathway is constantly functional or whether the virus is able to perform a pathway switching when cell surface caveolae are inhibited remains to be investigated.
The inhibitor experiments with genistein and PKC inhibitors revealed that tyrosine kinaseregulated phosphorylation events and activity of PKCα, enriched in caveolae (Mineo et al., 1998) , are involved in EV1 infection. PKCα and ERK activation has also been shown to play a role in EV1 uptake in the studies with another cell line, SAOS-α2β1 cells (Upla et al., 2004) . The results are in agreement with previous findings indicating that the local protein phosphorylation cascade in caveolae can be induced by microbial pathogens (Pelkmans et al., 2002; Sukumaran et al., 2002) . However, in contradiction to previous findings, showing that phosphatase inhibitors may enhance SV40 uptake through caveolae (Pelkmans et al., 2002) , sodium orthovanadate, a protein tyrosine phosphatase inhibitor, reduced the infectivity of EV1. Here, the drug may inhibit the alternative pathway of the EV1 entry, or it may affect the infection cycle after the initial entry step of the virus.
Although internalization of SV40 in caveolae requires depolymerization of cortical actin leading to formation of actin tails in CV-1 cells (Pelkmans et al., 2002) , our experiments with a concentration series of actin disturbing agents suggested that actin was a non-essential factor in EV1 infection in CV-1 cells. Cytochalasin D treatment has recently been described to prevent the antibody-induced movement of α2β1 integrin from lipid rafts to caveolae in SAOS-α2β1 cells, but in agreement with our results in CV-1 cells, it did not inhibit α2β1
integrin -mediated EV1 entry and infection (Upla et al., 2004) . These somewhat unexpected results favour the possibility that after its attachment to α2β1 integrin, located in the lipid rafts on the cell surface, EV1 could enter caveolin-1 positive intracellular organelles from the lipid rafts by an actin-independent manner. This would also explain why the virus is relatively infrequently found in cell surface caveolae in electron microscopy (our unpublished results).
However, one of these drugs, jasplakinolide that stabilizes actin polymers, caused a partial inhibition of EV1 infection in SAOS-α2β1 cells by retaining the virus and the integrin on the cell membrane (our unpublished results), suggesting that the detailed mechanisms of EV1 uptake from the cell surface to caveosomes may vary depending on the cell type.
The real-time fluorescence microscopy of AF-EV1 entry into GFP-caveolin-1-expressing cells demonstrated an increase in colocalization of the virus and caveolin-1 about 10 min after incubation at 37°C. The structures were mainly intracellular, thus most likely being caveolin-1-containing vesicles or caveosomes. The size and number of vesicles increased over time and they became more dynamic, as described earlier for caveosomes (Pelkmans et al., 2001) , with speeds up to 0.3 µm/s. Trafficking led to the formation of larger accumulations, both at the 27 cell periphery and in perinuclear regions. That the organelles were caveosomes was further confirmed by our finding that EV1 colocalized partially with CTX and SV40, which are known to be transported via caveosomes (Pelkmans et al., 2001; Nichols, 2002) . Moreover, nocodazole treatment that prevents the traffic of SV40 to smooth ER (Pelkmans et al., 2001) , increased the amount of colocalization of SV40 and EV1 in caveosomes. SV40 accumulates in caveosomes from 40 min to 3 h p.i. (Pelkmans et al., 2001) , while EV1 and CTX (Nichols, 2002 ) reach these structures in 10-20 min after binding to the cell surface. The difference in kinetics supports the notion that, in addition to the slow cell surface caveolar pathway described for SV40, EV1 can alternatively enter the caveosomes by a faster pathway.
The final cellular destination of EV1 capsid proteins has remained unclear because of the lack of colocalization with cellular markers used for the rough and smooth ER, the Golgi complex and lysosomes. SV40 and CTX are directed in a microtubule-dependent, nocodazole-sensitive manner from caveosomes to the ER or the Golgi complex (Pelkmans et al., 2001; Le and Nabi, 2003) . Even though tubular structures containing EV1 particles were occasionally observed in live microscopy, the infection was not affected by nocodazole, indicating that EV1 is not transported to the ER or the Golgi.
Brefeldin A, which inhibits several steps of SV40 entry via the caveolar route (Richards et al., 2002) , inhibit EV1 infectivity efficiently. However, in the presence of BFA, EV1 was able to reach the intracellular structures that were positive for caveolin-1 and that also accumulated SV40 during co-infection. Thus, it seems likely that the drug may either i) prevent the uncoating of the virus ii) stabilize the caveosomal membranes and hence prevent release of the viral genome to the cytoplasm or iii) prevent the formation of the viral replication complex, as reported for another enterovirus, poliovirus 1 (Maynell et al., 1992 ) .
Prior to replication in membrane-associated replication complexes in the cytoplasm (Bolten et al., 1998) , picornaviruses can release their RNA by several mechanisms. They may form a pore in the plasma membrane or in the membrane of an intracellular vesicle, through which the RNA is then extruded into the cytoplasm (Tosteson and Chow, 1997) , or they may uncoat in the acidic environment of endosomes (Schober et al., 1998) . For example, poliovirus 1 requires immediate receptor-induced conformational alterations for uncoating (Hogle, 2002) .
In contrast to many other picornaviruses studied, our sucrose density gradient analysis indicated that EV1 binding to the cell surface is somewhat inefficient in causing disassembly..
At the time of uncoating, after 1-2 h of uptake, the viral RNA was largely localized in caveosomes together with EV1 capsid proteins. We have also previously showed that the interaction of EV1 with the α2 integrin I domain does not induce conformational changes of the virus (Xing et al., 2004) and we have isolated an infectious virus from caveosomal vesicles (Marjomäki et al., 2002) . These observations suggest that viral capsid proteins and viral RNA are transported to caveosomes prior to the initiation of viral replication. Since the virus does not move to other cellular locations, such as the Golgi or the ER, the release of the viral genome to the cytoplasm could possibly occur through a pore formed in the caveosomal membrane or by caveosomal rupture. More detailed studies on the exact initiation mechanism of EV1 infection are required to illuminate the role of caveosomes in viral replication cycle.
Our results suggest that EV1 can utilize two distinct pathways of endocytic uptake into host cells. Both are dynamin-and lipid raft -dependent and can deliver the virus to caveosomes.
When compared to SV40, EV1 i) is internalized much faster, ii) does not require actin or microtubules, and, iii) it is not transported to the sER but may uncoat and release its genome into the cytosol at the level of the caveosome. Thus, the overall traffic of EV1 in the caveolar 29 pathway may be significantly different from SV40, a DNA virus that needs to be transported to the nucleus for replication, while release of the genome into the cytoplasm is sufficient for a positive-stranded RNA virus to initiate the replication cycle. FISH analysis confirmed that viral RNA localized in caveosomes from 30 min p.i. to 3 h p.i.
GFP-caveolin-1 (green)-transfected CV-1 cells were infected with EV1, and localization of viral RNA (red) was detected using the FISH technique. Bars: 20 µm.
